|
35. Cocconi G, Bella M, Zironi S et al. Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 1994; 12: 26872693. Webb A, Cunningham D, Scarffe JH et al. Randomized trial comparing epirubicin, cisplatin and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997; 15: 261267. Vanhoefer U, Rougier P, Wilke H et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000; 18: 2648 Sulkes A, Smyth J, Sessa C et al. Docetaxel Taxotere ; in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. Br J Cancer 1994; 70: 380383. Einzig AI, Neuberg D, Remick SC et al. Phase II trial of docetaxel Taxotere ; in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group ECOG ; results of protocol E1293. Med Oncol 1996; 13: 8793. Taguchi T, Sakata Y, Kanamaru R et al. Late phase II clinical study of RP56976 docetaxel ; in patients with advanced recurrent gastric cancer: a Japanese Cooperative Study Group trial group A ; . Gan To Kagaku Ryoho 1998; 25: 19151924. Mai M, Sakata Y, Kanamaru R et al. A late phase II clinical study of RP56976 docetaxel ; in patients with advanced or recurrent gastric cancer: a cooperative study group trial group B ; . Gan To Kagaku Ryoho 1999; 26: 487496. Mavroudis D, Kourousis C, Androulakis N et al. Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colonystimulating factor G-CSF ; : a phase II trial. J Clin Oncol 2000; 23: 341344. Roth AD, Maibach R, Martinelli G et al. Docetaxel Taxotere ; -cisplatin TC ; : an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research SAKK ; , and the European Institute of Oncology EIO ; . Ann Oncol 2000; 11: 301306. Ridwelski K, Gebauer T, Fahlke J et al. Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann Oncol 2001; 12: 4751. Kettner E, Ridwelski K, Keilholz U et al. Docetaxel and cisplatin combination chemotherapy for advanced gastric cancer: results of two phase II studies. Proc Soc Clin Oncol 2001; 20: 163 Abstr 657 ; . 46. Einzig AI, Lipsitz S, Wiernik PH, Benson AB 3rd. Phase II trial of taxol in patients with adenocarcinoma of the upper gastrointestinal tract UGIT ; . The Eastern Cooperative Oncology group ECOG ; results. Invest New Drugs 1995; 13: 223227. Ajani JA, Ilson DH, Kelsen DP. Paclitaxel in the treatment of patients with upper gastrointestinal carcinomas. Semin Oncol 1996; 23 5 Suppl 12 ; : 5558. 48. Ohtsu A, Boku N, Tamura F et al. An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer. J Clin Oncol 1998; 21: 416419. Murad AM, Petroianu A, Guimaraes RC et al. Phase II trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer: a novel, safe, and effective regimen. J Clin Oncol 1999; 22: 580586. Kim YH, Shin SW, Kim BS et al. Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma. Cancer 1999; 85: 295301. Ryoo BK, Kim TW, Choi SJ et al. A phase II trial of paclitaxel T ; and carboplatin C ; for advanced gastric cancer refractory to 5-fluorouracil F ; and cisplatin heptaplatin P ; . Proc Soc Clin Oncol 2001; 19: 128b Abstr 2262 ; . 52. Futatsuki K, Wakui A, Nakao I et al. Late phase II study of irinotecan hydrochloride CPT-11 ; in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group. Gan To Kagaku Ryoho 1994; 21: 1033 Kohne CH, Wils JA, Wilke HJ. Developments in the treatment of gastric cancer in Europe. Oncology Huntingt ; 2000; 14 12 Suppl 14 ; : 2225. 54. Lin L-S, Hecht JR. A phase II trial of irinotecan in patients with advanced adenocarcinoma of the gastroesophageal GE ; junction. Proc Soc Clin Oncol 2000; 19: 89a Abstr 1130 ; . 55. Shirao K, Shimada Y, Kondo H et al. Phase III study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. J Clin Oncol 1997; 15: 921927. Boku N, Ohtsu A, Shimada Y et al. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 1999; 17: 319323. Ajani JA, Baker J, Pisters PW et al. Irinotecan plus cisplatin in advanced gastric or gastroesophageal junction carcinoma. Oncology Huntingt ; 2001; 15 3 Suppl 5 ; : 5254. 58. Pozzo C, Bugat R, Peschel C et al. Irinotecan in combination with CDDP or 5-FU and folinic acid is active in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma: final results of a randomised phase II study. Proc Soc Clin Oncol 2001; 20: 134a Abstr 531 ; . 59. Grau JJ, Martn M, Gascn P et al. Phase II study of irinotecan CPT-11 ; and mitomycin C MMC ; combination in patients with advanced gastric cancer ENG ; . Preliminary results. Proc Soc Clin Oncol 2001; 20: 133b Abstr 2284 ; . 60. Findlay PN, Ackland S, Gebski V et al. Phase II study of irinotecan, leucovorin and 5FU ILF ; in advanced gastric cancer. Proc Soc Clin Oncol 2001; 20: 165a Abstr 655.
History of Mitomycin
APPENDIX B SAMPLING ERRORS . 217 APPENDIX C DATA QUALITY TABLES. 231 APPENDIX D 2003 NIGERIA DEMOGRAPHIC AND HEALTH SURVEY PERSONNEL . 237 APPENDIX E QUESTIONNAIRES . 243 APPENDIX F WORLD SUMMIT FOR CHILDREN INDICATORS . 333.
224a [p 528] De Marinis M., Accornero N.: Recurrent neck pain as a variant of migraine: description of four cases. J. Neurol. Neurosurg. Psychiatry 62, 669-670 1997.
1. Recommendations applies to all ages ; Ingested Material Minimum Fasting Period hrs ; Clear liquids 2 Breast milk 4 Infant formula 6 Non-human milk 6 Light solid foods 6 2. Recommendations apply to healthy patients exclusive of parturients undergoing elective surgery; following these recommendations does not guarantee gastric emptying has occurred. 3. Clear liquids include water, sugar-water, apple juice, non-carbonated soda, pulp-free juices, clear tea, black coffee. 4. Medications can be taken with up to 150 mL of water in the hour preceding induction of anesthesia.
Headaches Over 45 million Americans suffer from various types of headaches, including migraines and tension-types. Dr. Mednick can help identify the root cause of your headaches and guide you in the appropriate use of medications and other therapies, which can provide significant relief. Neurodegenerative Disorders, including Alzheimer's & Parkinson's Disease Dr. Mednick provides expert evaluation to determine the cause of memory loss and gait difficulties. He also offers essential guidance on the use of medications to manage these conditions. Multiple Sclerosis Dr. Mednick will help to determine if your symptoms are due to MS. A number of highly effective treatments are available, including Tysabri, an infusion IV ; therapy that can significantly reduce the severity of MS flare-ups and slow the progression of MS-related disability. Dr. Mednick works with an experienced registered nurse to safely administer Tysabri and other similar therapies in the comfort and convenience of his office. Seizures Epilepsy You'll find accurate evaluation and expert management for seizure disorders, plus caring and careful guidance in the use of anticonvulsant medications. Balance Disorders & Neuropathy Whether your condition is caused by diabetes or another medical issue, you'll find complete assessment and care right here. Dr. Mednick provides expert guidance on the most appropriate and effective treatments, including oral medications, infusion therapy and rehabilitation.
Drugs and combinations in trial include gemcitabine and cisplatin vinorelbine navelbine ; topotecan irinotecan, cisplatin and mitomycin c pemetrexed raltitrexed tomudex ; onconase most studies giving gemcitabine alone have not been successful and mitotane.
KAPLAN, W. D., 1953 The influence of Minutes upon somatic crossing over in Drosophila mlanogaster. Genetics 38: 6330-651 . MESELSOHN, 1964 On the mechanism of genetic recombination between DNA molecules. M., J. Mol. Biol. 9: 734-746. PLOUGH, H., 1924 Radium radiations and crossing over. Am. Naturalist 58: 85-87. H. SHInA, s. A. TERAWAKI, TAGUCHI, J. KAWAMATA, T. and 1959 Selective inhibition of formation of deoxyribonucleic acid in Escherichia coli by mitomycin C. Nature 183: 105&1057.
Mitomycin suppliers
Important that the agents utilized are effective and safe. Also, skin tolerability and compatibility of applied products, espe and modafinil.
Chronic therapy with nitrosoureas, other alkylating agents, mitomycin c therefore progessive reduction in dosages of myelosuppressive drugs is required treatment prevention a ; recombinant cytokines that stimulate cell production in bone marrow eg.
The most frequent serious complications of chemotherapy treatment are neutropenic fever and neutropenic sepsis. Although the nadir of neutropenia varies among drugs e.g. patients on docetaxel can become neutropenic two to three days after treatment, and the nadir for mitomycin C is several weeks after treatment ; , the risk of neutropenia should be considered at all times during the course of chemotherapy treatment. Patients with neutropenic fever or neutropenic sepsis must be treated promptly using the local policies for the empirical treatment. The treatment plan with intravenous antibiotics will usually include an aminoglycoside and an antipseudomonal antibiotic or a cephalosporin and vancomycin. Patients with an apparent site of infection, such as chest infection, urinary tract infection or central-line sepsis, should also receive an antibiotic with appropriate additional cover. Most patients with neutropenic fever will initially appear well, apart from the pyrexia, and they will respond to treatment with intravenous or oral antibiotics. However, a number of patients can either present or rapidly become seriously unwell with hypotension, shock and end-organ failure. In these patients, rapid assessment and management are essential. Volume replacement with intravenous fluids must be initiated, and consideration should be given to transfer to a high6 and modicon.
The microscopic lesions in both animals includ ed a necrotizing nephrosis Fig. 2 ; , recent hemor rhages as noted above, and marked atrophy of the mucosa of the colon as well as atypia and swelling of the epithelial cells in the small bowel Fig. 3 ; . The bone marrows showed only a slight depletion of hematopoietic elements. This seemed due to a deficiency of granulocytes and lymphocytes, since most of the cells present were immature. DISCUSSION The effects of mitomycin C are uniform in dif ferent mammalian species. Median lethal doses given parenterally in rats, cats, dogs, and monkeys vary within the narrow range of 1.0-2.5 mg kg. This compares closely with the total dose of 0.751.5 mg kg likely to produce serious signs of toxicity in cancer patients 3 ; . In all five laboratory spe cies lethal doses cause a protracted intoxication that is delayed in onset and characterized by anorexia, steady losses in weight, diarrhea, dehy dration, and delayed death. Similar effects have been seen in human beings 3 ; . Lesions in hematopoietic tissues and the intesti nal epithelium are the common pathologic changes in rats, dogs, and monkeys. They probably accout for most fatalities in these species as well as the major signs of toxicity in patients 3 ; . They are also the principal toxic effects of most antitumor agents. The close association of such lesions with chemotherapeutic activity is undoubtedly related to the fact that hematopoietic tissues and the intes tinal epithelium have the highest rates of prolifera tion found in the post-fetal mammalian organ ism 7 ; . There are several other effects of mitomycin C to be considered. The necrotizing nephrosis seen in monkeys was not found in dogs or rats, and clinical reports have not shown renal damage to occur in human beings 3, 15 ; . The fevers induced by mito mycin in dogs need further study. Most febrile episodes may have been due to secondary infec tions consequent to hematopoietic inhibition and agranulocytosis. Such associations have been seen in dogs treated with other bone marrow depres sants"for example, total-body exposure to ionizing radiations 2 ; and thioguanine 10 ; . However, in the present animals fever usually appeared before.
Mitomycin therapy
The one-year survival rate among breast cancer patients treated with taxotere was 49 percent, compared to 33 percent for those treated with the combination mitomycin c and vinblastine and molindone.
Ipm chemotherapy produces responses in renal cell cancer that stops responding to immunotherapy 6 8 2003 ; according to results recently published in the british journal of cancer , the chemotherapy combination consisting of camptosar® , platinol® and mitomycin produces anti-cancer responses and provides symptom relief in patients with advanced renal cell carcinoma that has stopped responding to immunotherapy.
Transferred to radioactive-free methionine-containing medium supplemented with 10% fetal bovine serum for the indicated time periods. Cells were then quickly washed twice with ice-cold phosphate-buffered saline and lysed in radioimmune precipitation assay buffer 1% phosphate-buffered saline, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS ; containing dissolved protease inhibitor tablets Roche Diagnostics ; . An equal amount of protein from each sample was immunoprecipitated with antibodies for the IGF-1R -subunit H-60 ; collected by protein A-Sepharose, resolved by SDSPAGE and visualized by autoradiography. 3.12 CELL VIABILITY ASSAY and moxifloxacin.
| Bladder cancer mitomycin cSpleen cells from normal AKR mice and from thymectomized, irradiated, bone marrowreconstituted AKR mice treated with burro antimouse thymocyte antiserum 3 and 2 days before sacrifice AKR-T ; were cultured at 4 X 10a cells 0.2 ml culture with nothing, PHA 1 #g ml ; , Con A 2 #g ml ; , LPS 10 ~g ml ; , and [~H]TdR incorporation was determined after 72 h. Some cells were treated with mitomycin C 50 #g ml ; for 30 min at 37C m ; or exposed to 2, 000 R X irradiation at 200 kVCP, half-value layer 0.9 x ; , and then washed four times before culture. sponse of these cells to lipopolysaccharide LPS ; is intact suggesting normal B-cell function 16 ; . Similar selective deletion of T-cell responses was demonstrated in cultures of all T cell-deficient populations used in the M L R described below. Table I also shows that A K R spleen cells treated with 5 0 z mitomycin C AKRm a n d DBAm ; have markedly reduced D N A synthetic responses, b u t are nevertheless capable of incorporating some [~H]thymidine [3H]TdR ; in response to the powerful T-cell mitogens, P H A a Con A, confirming reports of incomplete inactivation by mitomycin C 7, 18 ; . and D B A spleen cells treated with 2, 000 R irradiation AKRx a n d DBA~ ; are virtually incapable of D N synthesis even in response to mitogens. Two representative experiments comparing normal A K R spleen cells as responders in the M L R are presented in Table I I a. positive D N A.
Pharmaceutical agents causally associated with cancer in humans group 1 ; Of the 182 entries in Table I, 20 agents are classified as carcinogenic to humans 12 single drugs, five combinations and three groups or mixtures of chemicals ; . Eight of the 12 single drugs are cytostatic agents [chlornaphazine, myleran, chlorambucil, l- 2-chloroethyl ; -3- 4-methylcyclohexyl ; -l-nitrosourea methyl-CCNU ; , cyclophosphamide, melphalan, thiotepa, treosulfan], two are immunosuppressants azathioprine and cyclosporine ; , one is a non-steroidal oestrogen diethylstilboestrol ; , and one is a dermatological antiseptic arsenic trioxide ; . The combinations evaluated comprise analgesic formulations containing phenacetin, antineoplastic therapy with MOPP nitrogen mustard, vincristine, procarbazine and prednisone ; , oral contraceptives containing oestrogens and progestins as sequential or combined formulations, and the synergistic application of 8-methoxypsoralen with ultraviolet radiation A. Two groups of substances have been evaluated as carcinogenic, without specific reference to a single agent; these are steroidal and non-steroidal oestrogens, mainly when used as replacement therapy in postmenopausal women. Finally, the complex mixture of chemicals, coal-tars, that are applied locally to the skin for the treatment of some dermatological ailments are also carcinogenic. Pharmaceutical agents probably or possibly carcinogenic to humans groups 2A and 2B ; Category 2A contains 14 drugs that are considered to be carcinogenic to humans with a high degree of probability Table I ; . Most have been used or tested as antineoplastic agents [adriamycin, azacitidine, bischloroethyl nitrosourea BCNU ; , l- 2-chloroethyl ; -3-cyclohexyl-l-nitrosourea CCNU ; , chlorozotccin, cisplatin, nitrogen mustard, JV-nitroscHV-methylurea and procarbazine]. The others are the analgesic phenacetin, the antibacterial chloramphenicol, the anabolic steroids oxymetholone and testosterone, and 5-methoxypsoralen, which has been used for the treatment of psoriasis and is still used relatively often in cosmetic suntan preparations 36 ; . Category 2B contains many agents for which there is a somewhat lower degree of probability for carcinogenicity to humans. A total of 34 single chemicals, one combined formulation containing many agents together with the obsolete bactericidal dihydroxymethylfuratrizine ; and one collective group of drugs progestins ; have been evaluated as possible carcinogens. The single chemicals include many antineoplastic drugs azaserine, bleomycins, dacarbazine, daunomycin, merphalan, mitomycin C, nitrogen mustard N-oxide, streptozotocin, trichlormethine and uracil mustard ; , the sweetener saccharin, the anaesthetic chloroform, the analgesic phenazopyridine, the antibacterials nifuradene and furothiazole, the antifungal griseofulvin, the antiseptic 3-propiolactone, the antiprotozoans metronidazole and niridazole, the antiparasitics DDT and lindane, the dermatological agent safrole, the antianaemics iron--dextran complex and cobalt chloride, the a-blocker phenoxybenzamine, the central nervous system depressants phenobarbital and phenytoin, the antithyroid agents methylthiouracil, propylthiouracil and thiourea, the progestin medroxyprogesterone, the laxative dantron, the alkaloid monocrotaline from traditional herbal decoctions of Crotalaria sp. ; , a thiadiazole derivative used in gastritis, and finally two experimental agents lasiocarpine and nafenopin ; . 1752 and mrv.
Mitomycin pills
Bicarbonate orally 1.3 g 18 h before, 6 h prior and 30 min before and remove residual urinary residuum at the time of intravesical treatment ; TTR 28.1 mo and RFS 41%. G Dalbagni et al JCO 2002; 20: 3193-8 ; . GEM intravesical Phase I. MTD 2000 mg range 500-2000 ; at pH 5.5 to avoid toxicity, biwk x 3 q and then biopsy. N 18, refractory to BCG: 11 CR, minimal bladder irritation. R Colombo et al San Rafale, Milan ; JCO 2003; 21: 4270-6 ; . N 83. Randomization of N 83 Hyperthermia Medical Enterprises, Amsterdam; Synergo 101-1 ; + Mitomycin C 40 mg 50 mL Recurrences 17% ; vs Mitomycin C alone recurrences 57% ; . Similar side effects. A Giannopoulos et al Clin Ca Res 2003; 9: 5550-8 ; . N 123, with T1 Ta grade 3, with a M F 26.5 mo, randomized study comparing IFN alfa 1.5x10e7 IU wkly x 8, q 2 Tumor free 73.4%; cystitis at 6 mo showing T cell macrophage, leukocyte and NK infiltration ; vs MitoC 40 mg 50 mL and similar maintenance schedule Tumor free 57.2% ; . G Dalbagni et al JCO 2006; 24: 2729-34 ; . N 30, M F up 19 mo. GEM intravesical in BCG refractory superficial bladder cancer refusing cystectomy. GEM 2000 mg 100 mL tiwk x3, one wk rest and repeat once more. OR 15 50% MRFS 3.6 mo; 1yRFS 21%. Cystectomy after GEM 37%. * C Weiss et al JCO 2006; 24: 2318-24 ; Review high risk superficial bladder cancer defined as multiple in situ, grade III tumors, multiple focal lesions, tumor diameter 5cm and smaller tumors not qualifying if refractory to multiple TURs. In these cases TUR associated with a 80% recurrence and invasive tumors make up to 50-65% of them. BCG associated with a 30% recurrence rate. Cystectomy associate with a 70-90% cure rate with 20% morbidity and 1-4% mortality. Propose EBRT + ChX in T1 tumors fulfilling the mentioned criteria: EBRT 45-61.4 Gy and concurrent CDDP 25 mg m2 d or CBDCA ; x 5 + 5FU 600 mg m2 d x 5d, on d 1 and d 36 of EBRT. Results: CR 88% 121 137 ; , 5y tumor progression 19% and 10 y tumor progression 30%; 5yDFS 82%; In CR 89% and 79% respectively bladder preservation 80%; good urinary function 70.4%. Compared to BCG therapy is an improvement in 10% progression rate 25% to 15% ; and in 20% in recurrence rate 50% to 30% ; . * D Parekh et al MSKCC JCO 2006; 24: 5519-27 ; . Review series of superficial bladder cancer: Ta 60%, T1 30%, Tis 10%, after initial TUR a second TUR indicated a 40% persistant disease. Recurrence rate 70% up to 10 y and 30% of recurrences had progression to higher grade stage. ChX was MitoC initially; then BCG indicating a reduction of recurrence rate up to 50% in 5y and showing toxicity at high doses. Metanalysis of BCG reduction of 27% in progression rate but failure rate still 30%. Finally BCG + IFN alfa which indicated a reduction in recurrence rate 80%. Performed radical cystectomy when high grade recurrence or Cis refractory disease. BA Inman et al Cancer 2007; 109: 1499-505 ; . PDL1 Programmed cell death ligand 1, B7-H1 ; expresin correlated with poor prognosis in many tumor origins. PDL1 expression found very high in 11 12 patients with superficial bladder cancer who failed BCG and mitomycin.
Mitomycin bladder administration
|
